Form 4: Heron Therapeutics Exec Reports Stock Transaction

Heron Therapeutics, Inc. reports a transaction involving Chief Executive Officer Craig A. Collard, who acquired 13,797 shares of common stock.

Summary

• Craig A. Collard, Chief Executive Officer and Director of Heron Therapeutics, Inc., reported a transaction on April 19, 2026.
• Collard acquired 13,797 shares of common stock.
• This acquisition was made through the vesting of restricted stock units.
• Following this transaction, Collard beneficially owns 662,052 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard vesting of restricted stock units for executive compensation rather than an open market purchase or sale.

Positives

• Acquisition of 13,797 shares of common stock by the CEO indicates potential confidence in the company's future.
• The CEO's direct beneficial ownership increased to 662,052 shares, demonstrating a significant personal stake in the company.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transactions, such as this acquisition of common stock by a CEO, are often closely watched by investors as they can signal management's confidence in the company's prospects. This is a routine disclosure for executive compensation and ownership.

Stakeholder Impact

• Shareholders: The acquisition by the CEO may be viewed positively, reinforcing alignment between management and shareholder interests.

Key Dates

Keywords

Heron Therapeutics, HRTX, Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, CEO, Director, Beneficial Ownership